<DOC>
	<DOCNO>NCT01298375</DOCNO>
	<brief_summary>Type 2 diabetes ( T2D ) global burden disease affect almost 200 million people expect nearly double 2030 ( 1 ) . It imperative disease keep control , begin reverse direction incidence . We propose start identify physiological molecular aspect problem spectrum disease ( ie insulin sensitive athlete sedentary lean obese individual overt type 2 diabetic ) , focus effort examine difference identify stage progression possible target future intervention . The propose study `` Metabolic Phenotyping '' novel target population innovative use state-of-the-art technique . We hypothesize vivo difference metabolic flexibility mitochondrial function endurance athlete type 2 diabetic lean obese control retain vitro offer new model study underlie mechanism progression T2D .</brief_summary>
	<brief_title>Metabolic Phenotyping Humans</brief_title>
	<detailed_description>The aim present research proposal metabolically phenotype endurance train athlete , lean obese sedentary type 2 diabetic individual follow objective : 1. ass metabolic flexibility measure euglycemic-hyperinsulinemic clamp 2. measure vivo mitochondrial function MRS phosphocreatine ( PCr ) recovery 3. establish primary myoblast cell line correlate vivo measurement , well explore dietary , pharmacological genetic manipulation vitro 4. quantify intramyocellular lipid ( IMCL ) acetylcarnitine vivo MRS Study population : A total 132 male participant ( 18-70 year ) participate study . The first group 33 participant lean endurance-trained athlete , second group lean sedentary control participant , third group sedentary type 2 diabetic participant , last group 33 participant obese , non-diabetic sedentary control participant . It prefer use male participant order minimize variation measurement avoid confound factor hormone . Main study parameters/endpoints : The main study parameter difference metabolic flexibility measure euglycemic-hyperinsulinemic clamp , PCr recovery , IMCL acetylcarnitines measure MRS establishment primary myoblast cell line future use .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>General Inclusion criterion : Male sex Generally healthy specifically know cardiovascular disease gastric ulcer , affect study parameter Stable dietary habit ( weight loss/gain &gt; 3 kg last 6 month ) Group 1 , type 2 diabetes participant : Ages 4070 year BMI &gt; 30 kg/m2 Noninsulin dependent type 2 diabetes Must sulphonylurea ( SU ) derivate metformin therapy least six month constant dose least two month , dietary treatment least six month Wellcontrolled diabetes : HbA1c &lt; 8 % No diabetes related comorbidities like cardiovascular disease , diabetic foot , polyneuropathy , retinopathy Group 2 , obese healthy control participant : Ages 4070 year BMI &gt; 30 kg/m2 A plasma glucose level lower 6.1 mmol/L No family history diabetes No medication use Sedentary lifestyle ; No participation physical activity least 2 year Group 3 , endurance train athlete : Ages 1835 year BMI &lt; 25 kg/m2 No family history diabetes No medication use VO2max &gt; 55ml/kg/min Active competitive enduranceexercise activity , 3 time week least 2 year Stable level training least 6 month Group 4 , lean healthy sedentary control participant : Ages 1835 year BMI &lt; 25 kg/m2 No family history diabetes No medication use VO2max &lt; 55ml/kg/min Plasma glucose &lt; 6.1 mmol/L Sedentary lifestyle ; No participation physical activity 1 hour per week least 2 year General Exclusion criterion : Regular smoker Participation study Female sex Insulin dependent diabetic individual Participants diabetes related disease ( diabetic foot , diabetic polyneuropathy , diabetic retinopathy etc . ) Use Thiazolidines ( glitazone/rosiglitazone/pioglitazone/troglitazone ) Use anticoagulant ( thrombocyteaggregation inhibitor ) Aberrant ECG ( sign ischemia cardiac failure arrythmias ) Weight gain/loss &gt; 3 kg last 6 month HbA1c &lt; 7.8 type 2 diabetic individual Contraindications MRS scan : Electronic implant pacemaker neurostimulator Ironcontaining foreign body eye brain Some hearing aid artificial ( heart ) valve contraindicate MRS Claustrophobia Participants , want inform unexpected medical finding , wish physician inform , participate study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Metabolic flexibility</keyword>
	<keyword>Mitochondrial function</keyword>
	<keyword>Human primary myoblasts</keyword>
	<keyword>Lipid metabolism</keyword>
</DOC>